Related Experiment Video
Updated: Jan 14, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Clinical Efficacy and Challenges of Cancer-Testis Antigen Vaccines in Advanced Solid Tumors: A Systematic Review and
Jinting Jiang1, Lian Li2, Zhangneng Yu1
1Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Abstract:
Cancer-testis antigens (CTA) vaccines are being actively explored for advanced solid tumors, yet their clinical value remains uncertain. We conducted a systematic review and meta-analysis to December 21, 2024, synthesizing single-arm outcomes (objective response rate [ORR], disease control rate [DCR]) and randomized evidence for overall survival (OS) and disease-free survival (DFS) using random-effects models. Across 73 single-arm trials (n=1,435), the pooled ORR was 13.0% (95% CI 11.0-16.0; I²=32.7%) and the DCR was 39.0% (95% CI 34.0-44.0; I²=6.5%); higher ORRs were seen in melanoma (16.2%), with intravenous administration (22.4%), and with dendritic-cell platforms (19.3%). In 12 randomized trials, vaccination was associated with a modest improvement in OS (HR 0.80, 95% CI 0.66-0.97; I²=39.3%) but showed no significant difference in DFS (HR 0.98, 95% CI 0.89-1.08; I²=0%). Leave-one-out analyses were stable and Egger's test did not suggest small-study effects (OS p=0.315). Grade ≥3 adverse events occurred in 29.2% of patients, more often with combination therapy (35.4%) than monotherapy (22.7%); fatigue, rash, and fever were most common. Overall, CTA vaccination demonstrates modest antitumor activity with manageable toxicity, while heterogeneity by platform and route underscores the need for larger, contemporary randomized trials to refine indications.
Insights
Cancer-testis antigen (CTA) vaccines show modest antitumor activity in advanced solid tumors. While improving overall survival, further research is needed to optimize CTA vaccine strategies.
Area of Science:
- Oncology
- Immunotherapy
- Clinical Trials
Background:
- Cancer-testis antigen (CTA) vaccines are emerging as a therapeutic strategy for advanced solid tumors.
- The clinical efficacy and optimal application of CTA vaccines remain under investigation.
Purpose of the Study:
- To systematically review and meta-analyze the clinical value of CTA vaccines in advanced solid tumors.
- To synthesize outcomes from single-arm trials (objective response rate [ORR], disease control rate [DCR]) and randomized controlled trials (overall survival [OS], disease-free survival [DFS]).
Main Methods:
- Systematic review and random-effects meta-analysis of 73 single-arm trials (n=1,435) and 12 randomized trials.
- Data synthesis included pooled ORR, DCR, hazard ratios (HR) for OS and DFS.
- Assessed for small-study effects using Egger's test and conducted leave-one-out analyses.
Main Results:
- Pooled ORR was 13.0% and DCR was 39.0% across single-arm trials.
- CTA vaccination showed a modest improvement in OS (HR 0.80) but no significant difference in DFS (HR 0.98) in randomized trials.
- Higher ORRs were observed with specific platforms (dendritic-cell) and administration routes (intravenous), particularly in melanoma.
Conclusions:
- CTA vaccination demonstrates modest antitumor activity and manageable toxicity in advanced solid tumors.
- Heterogeneity in outcomes based on platform and administration route highlights the need for further investigation.
- Larger, contemporary randomized trials are essential to refine indications and optimize CTA vaccine efficacy.
More Related Videos
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...